CN101417086A - 一种治疗心肌缺血的中药制剂 - Google Patents
一种治疗心肌缺血的中药制剂 Download PDFInfo
- Publication number
- CN101417086A CN101417086A CNA2008101798634A CN200810179863A CN101417086A CN 101417086 A CN101417086 A CN 101417086A CN A2008101798634 A CNA2008101798634 A CN A2008101798634A CN 200810179863 A CN200810179863 A CN 200810179863A CN 101417086 A CN101417086 A CN 101417086A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- rhizoma
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 30
- 241000555712 Forsythia Species 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- 241000219780 Pueraria Species 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 8
- 108010052008 colla corii asini Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000167550 Centella Species 0.000 claims 4
- 241000545442 Radix Species 0.000 claims 4
- 241000189524 Baccharis halimifolia Species 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 25
- 240000001341 Reynoutria japonica Species 0.000 abstract description 16
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 16
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 15
- 229940010454 licorice Drugs 0.000 abstract description 15
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract description 12
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 12
- 235000017803 cinnamon Nutrition 0.000 abstract description 12
- 241000208688 Eucommia Species 0.000 abstract description 11
- 241001289529 Fallopia multiflora Species 0.000 abstract description 11
- 108010010803 Gelatin Proteins 0.000 abstract description 11
- 229920000159 gelatin Polymers 0.000 abstract description 11
- 239000008273 gelatin Substances 0.000 abstract description 11
- 235000019322 gelatine Nutrition 0.000 abstract description 11
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 11
- 241001061264 Astragalus Species 0.000 abstract description 10
- 241000092665 Atractylodes macrocephala Species 0.000 abstract description 10
- 244000146462 Centella asiatica Species 0.000 abstract description 10
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 10
- 235000006533 astragalus Nutrition 0.000 abstract description 10
- 210000004233 talus Anatomy 0.000 abstract description 10
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 9
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 8
- 244000197580 Poria cocos Species 0.000 abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 244000046146 Pueraria lobata Species 0.000 abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 5
- 244000061520 Angelica archangelica Species 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000007059 acute toxicity Effects 0.000 abstract description 2
- 231100000403 acute toxicity Toxicity 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 241000305492 Gastrodia Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 208000002193 Pain Diseases 0.000 description 28
- 210000002216 heart Anatomy 0.000 description 19
- 210000000952 spleen Anatomy 0.000 description 17
- 241000202807 Glycyrrhiza Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 108091006146 Channels Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 206010007247 Carbuncle Diseases 0.000 description 8
- 241000305491 Gastrodia elata Species 0.000 description 8
- 206010033557 Palpitations Diseases 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 244000132619 red sage Species 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 241000132012 Atractylodes Species 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 208000023589 ischemic disease Diseases 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000125175 Angelica Species 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 235000017276 Salvia Nutrition 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010008469 Chest discomfort Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001072909 Salvia Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 206010027339 Menstruation irregular Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 2
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- -1 isoflavone compound Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗心肌缺血的中药制剂,各种成分的重量份数比为:杜仲10~20份、羌活10~20份、葛根10~20份、丹参10~20份、当归10~20份、天麻10~20份、黄芪10~20份、虎杖10~20份、积雪草10~20份、川芎10~20份、茯苓10~20份、肉桂10~20份、白术10~20份、连翘10~20份、熟地10~20份、何首乌10~20份、阿胶10~20份、甘草10~20份。本发明治疗心肌缺血的中药制剂使用安全,无毒性,经急毒实验验证,无毒副作用,适用于不同体质的患者,可长期服用;本发明治疗心肌缺血的中药制剂无耐药性,无有依赖性的药物成分,因此病人长期服用也不会产生依赖性。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用配制品,特别涉及一种治疗心肌缺血的中药制剂。
背景技术
心肌缺血性疾病是一种常见的疾病,多发于中老年人群中,也是暂时丧失劳动能力以及具有劳动能力的人过早残废最常见的原因。其基本症状为心前区不适,隐痛,心慌,气急,胸闷,神疲易倦,周身肌肉酸痛,心律不齐等。中医学认为该病与心血亏损、气虚血瘀、邪热扰心有关。美国每年约有50万人死于本病,占本病人数1/3-1/2,占心脏病死亡人数的50-70%。我国发病率约在30%,占死亡人数的40%以上,且逐年增高,现已成为导致人口死亡的主要原因。
心肌缺血性疾病的发病随年龄的增长而增高,程度也随年龄的增长而加重。有资料表明,自40岁开始,每增加10岁,心肌缺血性疾病的患病率增1倍。男性50岁,女性60岁以后,冠状动脉硬化发展比较迅速,同样心肌梗塞的危险也随着年龄的增长而增长。
目前治疗心肌缺血性疾病的药物较多,常用的主要为化学药物,包括硝酸酯制剂、肾上腺素能β受体阻滞剂(β阻滞剂)、钙通道阻滞剂、抗血小板药物、调整血脂药物、抗凝药物。西药治疗常常导致一些不良反应,如诱发支气管哮喘,抑制心脏,引起心力衰竭等。治疗心肌缺血性疾病的中成药品种也不少,比较常用的有丹参制剂、复方银杏制剂、速效救心丸等等,这些药品有一定的治疗作用,但是存在一定的问题,主要是不同患者个体体质不完全相同,所以治疗时药物的疗效也不完全相同,有的甚至没有作用,而且这些药品中有些药物具有一定的耐药性,患者需要终身带药,这样影响患者的生活质量。
基于上述原因,研究一种安全、有效、快速的药物是行之有效的预防和治疗心肌缺血性疾病的一项重要任务。研制开发具有见效快、疗效确切、毒副作用小等特点的预防和治疗心肌缺血的药物以减少心血管疾病对人类健康的威胁是一项十分有意义的工作。
发明内容
本发明所要解决的技术问题在于克服目前在治疗心肌缺血性疾病上的不足之处,并提供一种取材容易、制备方便、费用低廉且治愈率较高的治疗心肌缺血的中药制剂。
为解决上述技术问题,本发明提供了一种治疗心肌缺血的中药制剂,各种成分的重量份数比为:杜仲10~20份、羌活10~20份、葛根10~20份、丹参10~20份、当归10~20份、天麻10~20份、黄芪10~20份、虎杖10~20份、积雪草10~20份、川芎10~20份、茯苓10~20份、肉桂10~20份、白术10~20份、连翘10~20份、熟地10~20份、何首乌10~20份、阿胶10~20份、甘草10~20份。
所述治疗心肌缺血的中药制剂,各种成分的重量份数比还可以为:杜仲10~15份、羌活10~15份、葛根10~15份、丹参10~15份、当归10~15份、天麻10~15份、黄芪10~15份、虎杖10~15份、积雪草10~15份、川芎15~20份、茯苓15~20份、肉桂15~20份、白术15~20份、连翘15~20份、熟地15~20份、何首乌15~20份、阿胶15~20份、甘草15~20份。
所述治疗心肌缺血的中药制剂,各种成分的重量份数比又可以为:杜仲15~20份、羌活15~20份、葛根15~20份、丹参15~20份、当归15~20份、天麻15~20份、黄芪15~20份、虎杖15~20份、积雪草15~20份、川芎10~15份、茯苓10~15份、肉桂10~15份、白术10~15份、连翘10~15份、熟地10~15份、何首乌10~15份、阿胶10~15份、甘草10~15份。
所述治疗心肌缺血的中药制剂,各种成分的重量份数比也可以为:杜仲10~15份、羌活10~15份、葛根10~15份、丹参10~15份、当归15~20份、天麻15~20份、黄芪15~20份、虎杖15~20份、积雪草15~20份、川芎15~20份、茯苓10~20份、肉桂10~20份、白术10~20份、连翘10~20份、熟地10~15份、何首乌10~15份、阿胶10~15份、甘草10~15份。
所述中药制剂的给药方式可以为口服。
所述中药制剂剂型可以为汤剂、散剂、蜜炼丸剂、水合丸剂,片剂、胶囊、口服液、颗粒剂或糖浆剂。
所述中药制剂的散剂的制备可以包括以下步骤:
将所述原料用水刷、洗干净,捞出晾干;
将当归、川芎、茯苓、肉桂、熟地分别放入砂锅小火炒5~10分钟,用粉碎机分别将其粉碎成细末,过筛;
将晾干后的杜仲、羌活、葛根、丹参、天麻、连翘、何首乌、阿胶分别送入切片机中切成小薄片,再将上述处理过的原料以及其余原料送入粉碎机粉碎成细末,过筛。
所述治疗心肌缺血的中药制剂,过筛所用的筛子可以为90~100目。
所述治疗心肌缺血的中药制剂,在粉碎机中粉碎的时间可以为10~20分钟。
所述中药制剂的散剂的制备进一步包括对混合后的细末采用紫外线照射进行消毒的步骤。
与现有技术相比,本发明的优点是:本发明配伍合理疗效显著,见效快,临床实验证明有效率高;本发明治疗心肌缺血的中药制剂使用安全,无毒性,经急毒实验验证,无毒副作用,适用于不同体质的患者,可长期服用;本发明治疗心肌缺血的中药制剂无耐药性,为中药制剂且选材细致,无有依赖性的药物成分,因此病人长期服用也不会产生依赖性。
具体实施方式
祖国医学认为:胸痹心痛可因七情内伤,饮食劳倦,外邪所容,正气虚衰等因而发。心主血脉,血脉不通,则心痛卒然而发;七情所伤,则气滞血瘀,心之络脉不通而发;外邪客于心之血脉,脉络绌急不通,卒然而痛;正虚无力帅血而行,血行瘀滞,亦可导致心痛。气机不利,则胸部窒塞憋闷,呼吸不利;心主神,心脉不畅,心神不安,故见心悸怔忡。尽管引发胸痹的原因不同,但瘀血内停,气郁不行,脉络失和,是胸痹心痛的共同病理环节。正如《素问·脉要精微论》曰:“脉者,血之府也,涩则心痛”。因而,活血行气,通脉止痛法,被广泛用于胸痹的治疗。
本发明治疗心肌缺血的中药制剂,各味药物的作用在于:
杜仲:治腰脊酸疼,肢体痿弱,遗精,滑精,五更泄泻,虚劳,小便余沥,阴下湿痒。王好古:“肝经气分。”《雷公炮制药性解》:“入肾经。”《本草经解》:“入手太阴肺经。”牛膝补肝肾,强筋骨,逐瘀通经,引血下行。用于腰膝酸痛,筋骨无力,经闭症瘕,肝阳眩晕。
羌活:散寒解表,祛风湿,止痛。辛温,气雄而散,发表力强,主散太阳经风邪及寒湿之邪,有散寒祛风、胜湿止痛之功,故善治风寒湿邪龙表,恶寒发热、肌表无汗、头痛项强、肢体酸痛者。
葛根:解表退热,生津,透疹,升阳止泻。用于外感发热头痛、高血压颈项强痛、口渴、消渴、麻疹不透、热痢、泄泻。《本草纲目》载:葛根,性凉、气平、味甘,具清热、降火、排毒诸功效。现代医学研究表明:葛根中的异黄酮类化合物葛根素对高血压、高血脂、高血糖和心脑血管疾病有一定疗效。
丹参:丹参能够促进组织的修复与再生,丹参能够促进纤维母细胞分化、胶原纤维形成较明显;肉芽形成比较成熟。局部淤血减轻、血液循环改善,愈合时间缩短。抑制过度增生对过度增生的纤维母细胞有抑制作用。
当归:补血活血,调经止痛,润肠通便。莪术破血行气止痛,温通力较大,可治疗血滞经闭腹痛、腹部包块、积聚,消积散结,行气消积止痛,破血祛瘀,行气止痛。
天麻:平肝息风止痉。用于头痛眩晕,肢体麻木,手足不遂,小儿惊风,癫痫抽搐,破伤风。
黄芪补气升阳,托疮生肌;用于温养脾胃而生肌,用于气血不足,疮疡内陷,久溃不敛;健脾益气,且有调节机体的免疫功能。
虎杖、微苦,微寒。归肝、胆、肺经。祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,症瘕,水火烫伤,跌扑损伤,痈肿疮毒,咳嗽痰多。《本草述》:虎杖之主治,其行血似与天名精类,其疗风似与王不留行类,第前哲多谓其最解暑毒,是则从血所生化之原以除结热,故手厥阴之血脏与足厥阴之风脏,其治如鼓应桴也。方书用以疗痉病者,同于诸清热之味,以其功用为切耳,然于他证用之亦鲜,何哉?方书用以治淋,即丹溪疗老人气血受伤之淋,亦以为要药,于补剂中用之矣。谓虚人服之有损者,与补剂并行,其庶几乎。
积雪草苦、辛,寒。归肝、脾、肾经。清热利湿,解毒消肿。用于湿热黄疸,中暑腹泻,砂淋血淋,痈肿疮毒,跌扑损伤。
川芎辛,温。归肝、胆、心包经。活血行气,祛风止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《别录》:"除脑中冷动,面上游风去来,目泪出,多涕唾,忽忽如醉,诸寒冷气,心腹坚痛,中恶,卒急肿痛,胁风痛,温中内寒。"《药性论》:"治腰脚软弱,半身不遂,主胞衣不出,治腹内冷痛。"《日华子本草》:"治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破症结宿血,养新血,长肉,鼻洪,吐血及溺血,痔瘘,脑痈发背,瘰疬瘿赘,疮疥,及排脓消瘀血。"
茯苓性甘、平、淡,具有利水渗湿、健脾、安神的功能。并能促进人体的免疫功能;乙醚或乙醇提取物能使离体蛙心收缩加强,对家兔血糖则先使升高而后降低。茯苓煎剂对小鼠有镇静作用。
肉桂性大热,味辛、甘。补火助阳,引火归源,散寒止痛,活血通经。用于阳痿、宫冷、心腹冷痛、虚寒吐泻、经闭、痛经、温经通脉。《本草拾遗》:箘桂、牡桂、桂心,已上三色,并同是一物。按桂林、桂岭,因桂为名,今之所生,不离此郡。从岭以南际海,尽有桂树,惟柳、象州最多。味即辛烈,皮又厚坚,厚者必嫩,薄者必老。以老薄者为一色,以厚嫩者为一色,嫩即辛香,兼又筒卷;老必味淡,自然板薄。板薄者,即牡桂也,以老大而名焉;筒卷者,即箘桂也,以嫩而易卷。古方有筒桂,字似箘字,后人误而书之,习而成俗,至于书传,亦复因循。桂心即是削除皮上甲错,取其近里,辛而有味。
白术性苦、甘、咸、寒,具有清热、解毒、养阴之功能。白术具有健脾益气,燥湿利水,止汗,安胎的功效。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。《医学启源》记载:“除湿益燥,和中益气,温中,去脾胃中湿,除胃热,强脾胃,进饮食,止渴,安胎。”
连翘苦,微寒。归肺、心、小肠经。清热解毒,消肿散结。用于痈疽,瘰疬,乳痈,丹毒,风热感冒,温病初起,温热入营,高热烦渴,神昏发斑,热淋尿闭。连翘药用部分主要是果实。它的果壳,即“羚翘解毒丸”中的“翘”。含有连翘酚、香豆精、齐墩果酸、皂甙、维生素P等。具有清热、解毒、散结排脓等功效。主治温热、疮疡、瘰疬、丹毒、班疹、流感。
熟地味甘,性微温。归肝、肾经。具有补血滋阴功效。用于血虚萎黄,眩晕,心悸失眠,月经不调,崩漏等症。可用于肾阴不足的潮热骨蒸、盗汗、遗精、消渴等;补精益髓功效用于肝肾精血亏虚的腰膝酸软,眩晕耳鸣,须发早白等。
何首乌苦、甘、涩,温。归肝、心、肾经。解毒,消痈,润肠通便。用于瘰疠疮痈,风疹瘙痒,肠燥便秘;高血脂。现代医学研究表明,何首乌具有增强免疫的功能。何首乌对强的松龙和环磷酰胺引起的老年小鼠脾、胸腺抑制性改变有明显对抗作用,使脾巨噬细胞的吞噬率和吞噬指数明显提高。饲喂首乌乙醇浸膏能明显提高老年大鼠外周淋巴细胞DNA的损伤修复能力。小鼠灌服制首乌6g/kg,连续给药7日,能明显提高腹腔巨噬细胞的吞噬能力,对强的松龙引起的吞噬指数下降,有明显的对抗作用。何首乌水煎醇提物对小鼠T淋巴细胞及B淋巴细胞免疫功能均有增强作用,前者作用更为显著。何首乌提取物25-100mg/kg,腹腔注射,连续给药3日,可显著提高正常小鼠由ConA诱导的胸腺和脾脏T淋巴细胞增殖反应;皮下注射5-100g/kg,连续3日,可明显增加正常小鼠脾脏抗体形成细胞数,以50g/kg组作用最显著。
阿胶甘,平。《本经》:"味甘,平。"《别录》:"微温,无毒。"《医学启源》:"《主治秘诀》云,性平,味淡。"入肺、肝、肾经。滋阴补血,安胎。治血虚,虚劳咳嗽,吐血,衄血、便血,妇女月经不调,崩中,胎漏。《本经》:"主心腹内崩,劳极洒洒如疟状,腰腹痛,四肢酸疼,女子下血。安胎。久服益气。"《别录》:"丈夫小腹痛,虚劳羸瘦,阴气不足,脚酸不能久立,养肝气。"《药性论》:"主坚筋骨,益气止痢。"《千金·食治》:"治大风。"
甘草甘,平。归心、肺、脾、胃经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。甘草性味甘,平。人心、肺、脾、胃经。入药能泻火解毒、润肺祛痰止咳,益气补中、缓急止痛、缓和药性,用于治疗心气不足、心悸怔忡、脉结代、脾胃虚弱、气血不足、倦怠无力,以及腹中痉挛急疼痛等症。甘草的药性缓和,可升、可降,可以与补药、泻药、寒药、温药、凉药等各类药物配合使用,并有调和药性的作用。西医药理发现,甘草剂有抗炎和抗变态反映的功能,因此在西医临床上主要作为缓和剂。缓解咳嗽,祛痰,治疗咽痛喉炎;甘草或甘草次酸有去氧皮质酮类作用,对慢性肾上腺皮质功能减退症有良好功效;甘草制剂能促进胃部粘液形成和分泌,延长上皮细胞寿命,有抗炎活性,常用于慢性溃疡和十二指肠溃疡的治疗;甘草的黄酮具有消炎、解痉和抗酸作用。
心肌缺血性疾病多发于40岁以上的中老年人,人过中年,正气渐衰,且活血行气诸药,性多开破,易伤正气,故佐以益气养阴扶正之品,既可扶正以祛邪,又可祛邪而不伤正,相是益彰。气滞血瘀之胸痹,乃瘀血气滞交相为患。气帅血行,气滞则血瘀;瘀血阻遏,气机不畅。瘀血气滞痹阻心脉,气血不通,故卒然而痛。针对上述病机,本方主要功能是行气活血。行气与活血并重,配伍严谨,祛邪与扶正并施,共奏理气化瘀、补益气血、调理脾胃之功。
本发明治疗心肌缺血的中药制剂按照下述方法制备散剂剂型的药物:
将所述原料用水刷、洗干净,捞出晾干;
将当归、川芎、茯苓、肉桂、熟地分别放入砂锅小火炒5~10分钟,用粉碎机分别将其粉碎10分钟,待其成细末,100目筛子过筛;
将晾干后的杜仲、羌活、葛根、丹参、天麻、连翘、何首乌、阿胶分别送入切片机中切成小薄片,再将上述处理过的原料以及其余原料送入粉碎机粉碎20分钟,待其成细末,90目过筛,过筛后的细末采用紫外线照射进行消毒,分包待用。
药效学实验:
该药对小鼠耐缺氧能力的保护作用:试验小鼠120只,雄性,动物末次给药后每组随机再分为常压、常压+ISO和低压三种条件下进行试验,结果用表明该药治疗8天,具有明显增强小鼠耐缺氧能力。
对垂体后叶素所致大鼠心肌缺血的影响:动物实验表明,对缺血前后的血压、心率及心电图阳性检出率的实验表明该药能明显对抗垂体后叶素引起的心肌缺血症状。对于有垂体后叶素引起的血清乳酸脱氢同工酶的改变表明对心肌有明显的保护作用。
对大鼠血清总胆固醇和血小板聚集和粘附功能的影响:动物实验表明能显著降低血清和肝脏胆固醇含量,能显著改善血小板的聚集和粘附功能。
对小鼠应激能力的影响:64只大鼠随机分组治疗6天后,除正常组外,其余各组造成血瘀动物模型,次日给药治疗后测全血比粘度,血浆比粘度,红细胞压积百分率,红细胞聚积指数等指标。结果表明该药对血瘀大鼠高切变率,低切变率,RBC聚积指数和血浆比粘度与对照比较有明显改善作用。
对大鼠心脏功能及血流动力学的影响:可明显增加正常大鼠的CO、CI,小剂量该药尚可升高LVSP,以35分钟显著。对其他心脏功能及血流动力学指标无明显影响。
对缺血心肌功能、代谢和形态的影响:
1、该药对缺血大鼠心脏功能及血流动力学的影响:实验证明,MI(心肌梗死)组在梗塞后35分钟,50分钟时平均动脉压、Lvsp、-dp/atmax、CO、CI等均显著降低,而该药可使MI后的平均动脉压,LVSP、+dp/dtmax、CO、CI等增大,以小剂量组最显著。
2、对急性缺血心肌形态变化的影响:从镜检结果可见,各梗塞及梗塞干预组均有灶壮心肌梗死;MI组为9/10例,小剂量组为2/8例,大剂量组为5/11例,阳性对照组为6/11例,说明本发明中药制剂有减轻心肌坏死的作用。
典型病例1:张女士,48岁,患病5年,胸闷气短,胸痛失眠,头晕心悸,乏力,舌暗苔腻,脉沉细。使用如下配方:
杜仲10g、羌活10g、葛根10g、丹参10g、当归10g、天麻10g、黄芪10g、虎杖10g、积雪草10g、川芎10g、茯苓10g、肉桂10g、白术10g、连翘10g、熟地10g、何首乌10g、阿胶10g、甘草10g。
经服本发明中药汤剂35剂症状明显减轻,至今未复发。
典型病例2:汪女士,53岁,患者自述近几个月来,感觉心口发闷,心跳有时跳得很厉害,左胸刺痛,有时痛引背部,苔暗脉弦细,证属心血瘀阻。使用如下配方:
杜仲10g、羌活10g、葛根10g、丹参10g、当归10g、天麻10g、黄芪10g、虎杖10g、积雪草10g、川芎15g、茯苓15g、肉桂15g、白术15g、连翘15g、熟地15g、何首乌15g、阿胶15g、甘草15g。
采用本发明中药内服汤药,先服20剂,症状明显好转,继而又服20剂,心口发闷以及左胸刺痛等症状基本消失。6个月后追访,未见复发。
典型病例3,赵先生,63岁,三年前开始患病,症为冠心病,气喘胸闷憋气,陈发性痛疼,有时反射到背部,四肢厥冷,浑身乏力,多次反复发作。使用如下配方:
杜仲15g、羌活15g、葛根15g、丹参15g、当归15g、天麻15g、黄芪15g、虎杖15g、积雪草15g、川芎10g、茯苓10g、肉桂10g、白术10g、连翘10g、熟地10g、何首乌10g、阿胶10g、甘草10g。
经服本发明中药汤剂40剂症状明显减轻,后又服用本发明中药散剂1月,巩固疗效,至今四年未复发。
典型病例4:冷男士,61岁,患者冠心病心绞痛病史二年,近一月来发作频繁,每周3~5次,每次持续约5~6分钟,动则胸痛、心悸,胸闷憋气,烦热躁动,自服“复方丹参滴丸”可缓解,痛甚时则需含服“硝酸甘油片”。临床诊断为冠心病心绞痛,属心脉瘀热证。使用如下配方:
杜仲10g、羌活10g、葛根10g、丹参10g、当归15g、天麻15g、黄芪15g、虎杖15g、积雪草15g、川芎15g、茯苓10g、肉桂10g、白术10g、连翘10g、熟地10g、何首乌10g、阿胶10g、甘草10g。
经服本发明中药散剂40剂,治疗后复查心电图V4-6ST段恢复,T波较为直立平坦,治疗过程中未出现不良反应。
以上各实例配方是发明人根据不同病人的病情及身体状况,运用的典型配方,经过配制,泡制成散剂,或丸剂,或汤剂,一般2剂服3天,饭后服用,一个月为一疗程,经90例冠心病(包括心绞痛、心肌梗死)患者试用观察,2-4个疗程均取得比较满意的效果,临床疗效观察,有效率达88.9%,经追访基本无复发。
Claims (10)
1、一种治疗心肌缺血的中药制剂,其特征在于,各种成分的重量份数比为:杜仲10~20份、羌活10~20份、葛根10~20份、丹参10~20份、当归10~20份、天麻10~20份、黄芪10~20份、虎杖10~20份、积雪草10~20份、川芎10~20份、茯苓10~20份、肉桂10~20份、白术10~20份、连翘10~20份、熟地10~20份、何首乌10~20份、阿胶10~20份、甘草10~20份。
2、根据权利要求1所述治疗心肌缺血的中药制剂,其特征在于,各种成分的重量份数比为:杜仲10~15份、羌活10~15份、葛根10~15份、丹参10~15份、当归10~15份、天麻10~15份、黄芪10~15份、虎杖10~15份、积雪草10~15份、川芎15~20份、茯苓15~20份、肉桂15~20份、白术15~20份、连翘15~20份、熟地15~20份、何首乌15~20份、阿胶15~20份、甘草15~20份。
3、根据权利要求1所述治疗心肌缺血的中药制剂,其特征在于,各种成分的重量份数比为:杜仲15~20份、羌活15~20份、葛根15~20份、丹参15~20份、当归15~20份、天麻15~20份、黄芪15~20份、虎杖15~20份、积雪草15~20份、川芎10~15份、茯苓10~15份、肉桂10~15份、白术10~15份、连翘10~15份、熟地10~15份、何首乌10~15份、阿胶10~15份、甘草10~15份。
4、根据权利要求1所述治疗心肌缺血的中药制剂,其特征在于,各种成分的重量份数比为:杜仲10~15份、羌活10~15份、葛根10~15份、丹参10~15份、当归15~20份、天麻15~20份、黄芪15~20份、虎杖15~20份、积雪草15~20份、川芎15~20份、茯苓10~20份、肉桂10~20份、白术10~20份、连翘10~20份、熟地10~15份、何首乌10~15份、阿胶10~15份、甘草10~15份。
5、根据权利要求1~4中任一项所述治疗心肌缺血的中药制剂,其特征在于,所述中药制剂的给药方式为口服。
6、根据权利要求1~4中任一项所述治疗心肌缺血的中药制剂,其特征在于,所述中药制剂剂型为汤剂、散剂、蜜炼丸剂、水合丸剂,片剂、胶囊、口服液、颗粒剂或糖浆剂。
7、根据权利要求1~4中任一项所述治疗心肌缺血的中药制剂,其特征在于,所述中药制剂的散剂的制备包括以下步骤:
将所述原料用水刷、洗干净,捞出晾干;
将当归、川芎、茯苓、肉桂、熟地分别放入砂锅小火炒5~10分钟,用粉碎机分别将其粉碎成细末,过筛;
将晾干后的杜仲、羌活、葛根、丹参、天麻、连翘、何首乌、阿胶分别送入切片机中切成小薄片,再将上述处理过的原料以及其余原料送入粉碎机粉碎成细末,过筛。
8、根据权利要求7所述治疗心肌缺血的中药制剂,其特征在于,过筛所用的筛子为90~100目。
9、根据权利要求7所述治疗心肌缺血的中药制剂,其特征在于,在粉碎机中粉碎的时间为10~20分钟。
10、根据权利要求7所述治疗心肌缺血的中药制剂,其特征在于,所述中药制剂的散剂的制备进一步包括对混合后的细末采用紫外线照射进行消毒的步骤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101798634A CN101417086B (zh) | 2008-12-03 | 2008-12-03 | 一种治疗心肌缺血的中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101798634A CN101417086B (zh) | 2008-12-03 | 2008-12-03 | 一种治疗心肌缺血的中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101417086A true CN101417086A (zh) | 2009-04-29 |
CN101417086B CN101417086B (zh) | 2011-03-09 |
Family
ID=40628212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101798634A Expired - Fee Related CN101417086B (zh) | 2008-12-03 | 2008-12-03 | 一种治疗心肌缺血的中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101417086B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103212044A (zh) * | 2013-04-08 | 2013-07-24 | 姜玉芝 | 一种治疗心血管疾病的中药组合物 |
CN103330911A (zh) * | 2012-03-31 | 2013-10-02 | 李浩成 | 治疗冠心病的中药组合物粉剂及其制备方法 |
CN103385967A (zh) * | 2013-07-19 | 2013-11-13 | 苏州市天灵中药饮片有限公司 | 一种包含何首乌的中药及其制备方法 |
CN104288709A (zh) * | 2014-11-11 | 2015-01-21 | 邵明涛 | 用于心绞痛的中成药物制剂 |
CN104306901A (zh) * | 2014-11-11 | 2015-01-28 | 邵明涛 | 一种用于心绞痛的中药制剂的制备方法 |
EP3701961A4 (en) * | 2017-10-27 | 2021-07-21 | National Institute for Korean Medicine Development | ANTITHROMBOTIC COMPOSITION CONTAINING JAPANESE KNOTWEAR AND CINNAMOMUM CASSIA BLUME |
-
2008
- 2008-12-03 CN CN2008101798634A patent/CN101417086B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103330911A (zh) * | 2012-03-31 | 2013-10-02 | 李浩成 | 治疗冠心病的中药组合物粉剂及其制备方法 |
CN103330911B (zh) * | 2012-03-31 | 2014-12-17 | 韩笑峰 | 治疗冠心病的中药组合物粉剂及其制备方法 |
CN103212044A (zh) * | 2013-04-08 | 2013-07-24 | 姜玉芝 | 一种治疗心血管疾病的中药组合物 |
CN103212044B (zh) * | 2013-04-08 | 2015-04-01 | 周丽英 | 一种治疗心血管疾病的中药组合物 |
CN103385967A (zh) * | 2013-07-19 | 2013-11-13 | 苏州市天灵中药饮片有限公司 | 一种包含何首乌的中药及其制备方法 |
CN104288709A (zh) * | 2014-11-11 | 2015-01-21 | 邵明涛 | 用于心绞痛的中成药物制剂 |
CN104306901A (zh) * | 2014-11-11 | 2015-01-28 | 邵明涛 | 一种用于心绞痛的中药制剂的制备方法 |
EP3701961A4 (en) * | 2017-10-27 | 2021-07-21 | National Institute for Korean Medicine Development | ANTITHROMBOTIC COMPOSITION CONTAINING JAPANESE KNOTWEAR AND CINNAMOMUM CASSIA BLUME |
Also Published As
Publication number | Publication date |
---|---|
CN101417086B (zh) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103251867B (zh) | 一种治疗糖尿病的中药复方药物及其制备方法 | |
CN104940740A (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 | |
CN101417086A (zh) | 一种治疗心肌缺血的中药制剂 | |
CN103736018A (zh) | 一种治疗胆结石的药物及其制备方法 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN104189811A (zh) | 一种治疗产后血晕的中药组合物及其制备方法 | |
CN104127756A (zh) | 健脾止泻膏 | |
CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
CN104645249B (zh) | 一种治疗冠心病心绞痛的药物 | |
CN103479969A (zh) | 一种治疗癫狂病的药物及其制备方法 | |
CN103330837B (zh) | 一种治疗绝经妇女骨质疏松症的中药组合物 | |
CN102416121B (zh) | 一种药物组合物在制备治疗胃溃疡的药物中的用途 | |
CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
CN101204494B (zh) | 一种治疗慢性肠炎的药物 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN104042981A (zh) | 一种治疗产后便秘的药剂及制备方法 | |
CN105999058A (zh) | 鬼针草降脂片 | |
CN105535839A (zh) | 一种治疗结肠癌的中药片剂及其制备方法 | |
CN105213905A (zh) | 一种防治绝经后骨质疏松症的中药组合物及其应用 | |
CN109078157A (zh) | 一种抗肿瘤药物及其制备方法 | |
CN103656199B (zh) | 一种治疗肾阴不足证型咳嗽的中药 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN103110806A (zh) | 一种治疗更年期综合症的药物 | |
CN105125860A (zh) | 一种有效治疗骨质疏松的制剂 | |
CN105106913A (zh) | 一种治疗脾肾阳虚型慢性结肠炎的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110309 Termination date: 20111203 |